Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, I-SPY 2 Trial Consortium, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF. · 2022
Read Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. by Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, I-SPY 2 Trial Consortium, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9455620.txt.
Introduction
Yau and co-authors pool patient data to test residual cancer burden after chemotherapy in breast cancer. The RCB score grades cancer left after drug treatment before surgery. Single studies had tied it to outlook. Whether it held across subtypes and settings needed a bigger test.
The analysis merged data from 12 institutes and trials. It covered 5161 patients who had chemotherapy before surgery. Median follow-up ran to 56 months, with 1164 event-free survival events. Higher RCB scores meant worse event-free survival in every subtype. The link held after adjusting for age, grade, and stage factors. Hazard ratios per unit of score ranged from 1.52 to 2.09 in adjusted models. The authors back RCB as a broad prognosis tool.
Catalog record
| CREATOR | Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, I-SPY 2 Trial Consortium, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients By Christina Yau, Marie Osdoit, Marieke van der Noordaa, Sonal Shad, Jane Wei, Diane de Croze, Anne-Sophie Hamy, Marick Laé, Fabien Reyal, Gabe S Sonke, Tessa G Steenbruggen, Maartje van Seijen Published in: The Lancet. Oncology DOI: 10.1016/S1470-2045(21)00589-1 ABSTRACT Summary Background Previous studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate the relationship of RCB with long-term prognosis across different phenotypic subtypes of breast cancer, to assess generalisability in a broad range of practice settings. Methods In this pooled analysis, 12 institutes and trials in Europe and the USA were identified by personal communications with site investigators. We obtained participant-level RCB results, and data on clinical and pathological stage, tumour subtype and grade, and treatment and follow-up in November, 2019, from patients (aged ≥18 years) with primary stage I–III breast cancer treated with neoadjuvant chemotherapy followed by surgery. We assessed the association between the continuous RCB score and the primary study outcome, event-free survival, using mixed-effects Cox models with the incorporation of random RCB and cohort effects to account for between-study heterogeneity, and stratification to account for differences in baseline hazard across cancer subtypes defined by hormone receptor status and HER2 status. The association was further evaluated within each breast cancer subtype in multivariable analyses incorporating random RCB and cohort effects and adjustments for age and pretreatment clinical T category, nodal status, and tumour grade. Kaplan-Meier estimates of event-free survival at 3, 5, and 10 years were computed for each RCB class within each subtype. Findings We analysed participant-level data from 5161 patients treated with neoadjuvant chemotherapy between Sept 12, 1994, and Feb 11, 2019. Median age was 49 years (IQR 20–80). 1164 event-free survival events occurred during follow-up (median follow-up 56 months [IQR 0–186]). RCB score was prognostic within each breast cancer subtype, with higher RCB score significantly associated with worse event-free survival. The univariable hazard ratio (HR) associated with one unit increase in RCB ranged from 1·55 (95% CI 1·41–1·71) for hormone receptor-positive, HER2-negative patients to 2·16 (1·79–2·61) for the hormone receptor-negative, HER2-positive group (with or without HER2-targeted therapy; p<0·0001 for all subtypes). RCB score remained prognostic for event-free survival in multivariable models adjusted for age, grade, T category, and nodal status at baseline: the adjusted HR ranged from 1·52 (1·36–1·69) in the hormone receptor-positive, HER2-negative group to 2·09 (1·73–2·53) in the hormone receptor-negative, HER2-positive group (p<0·0001 for all subtypes). Interpretation RCB score and class were independently prognostic in all subtypes of breast cancer, and generalisable to multiple practice settings. Although variability in hormone receptor subtype definitions and treatment across patients are likely to affect prognostic performance, the association we observed between RCB and a patient’s residual risk suggests that prospective evaluation of RCB could be considered to become part of standard pathology reporting after neoadjuvant therapy. INTRODUCTION Neoadjuvant chemotherapy was introduced for patients with locally advanced inoperable breast cancer in the late 1970s.1 Neoadjuvant chemotherapy is at least as effective as adjuvant therapy and has several additional advantages.2 Compared with adjuvant therapy, neoadjuvant therapy permits less extensive breast and axillary surgery by downstaging the tumour and allows monitoring of the treatment response, which provides important prognostic information. Pathological complete response (pCR) to neoadjuvant chemotherapy, defined as the absence of residual invasive disease in the breast and axilla, is strongly associated with improved long-term survival outcomes.3–5 The influential meta-analysis of the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) showed that patients with pCR have improved event-free survival and overall survival, with the greatest prognostic value in patients with highly proliferative tumours.4 Consequently, the US Food and Drug Administration and European Medicines Agency issued initial guidance in 2012–14 for the use of pCR as a regulatory endpoint for accelerated approval of new drugs for neoadjuvant chemotherapy of breast cancer. Since these guidances were issued, contemporary trials have incorporated standardised pathological assessments of surgical resection specimens and validated pCR as a reliable prognostic marker.6 Increasingly, the presence or absence of residual disease is being used to guide adjuvant decisions following neoadjuvant chemotherapy.7,8 The binary outcome of pCR versus residual disease confers little information, offering no distinction among patients with varied amounts of residual disease. Furthermore, methods to evaluate surgical specimens and report residual disease have not been adequately standardised within pathology practice. The residual cancer burden (RCB) method, first described in 2007, was designed to address these shortcomings by providing a standard set of methods to evaluate and quantify the extent of residual disease in breast and axillary lymph nodes following neoadjuvant chemotherapy.9 It yields a continuous score, with pCR being the equivalent of an RCB score of zero. Empirically derived cutpoints are applied to the continuous score to define four RCB classes, from RCB-0 to RCB-3, that represent an increasing residual disease burden. RCB assessments are highly reproducible between pathologists;10,11 and both RCB and its classes have been validated as prognostic in single-institution studies12–15 and multicentre trials.16–19 However, individually, these cohorts are too small to obtain accurate estimates of prognosis related to RCB within the various subtypes of breast cancer. Therefore, we performed a pooled participant-level analysis of multiple clinical trials and cohorts to evaluate the overall association between RCB and long-term outcomes, with emphasis on the breast cancer subtypes defined by hormone receptor and HER2 receptor status. Our aim was to understand the prognostic value of RCB relative to pCR in the context of breast cancer subtypes, to optimise the interpretation of RCB and better inform patient management across a broad array of practice settings. METHODS Study design and patient cohorts In this pooled analysis, 12 institutes and trials in Europe and the USA were identified by personal communications with site investigators. For inclusion in this pooled analysis of participant-level data, trials or cohorts were required to include adult patients (aged ≥18 years) with primary stage I–III breast cancer (no positive sentinel lymph node biopsy, any phenotypic subtype) treated with neoadjuvant chemotherapy followed by surgery; and have available data for RCB, and follow-up data to evaluate the primary endpoint of event-free survival and the secondary endpoint of distant relapse-free survival. Data on Eastern Cooperative Oncology Group performance status was not available in all patients and thus was not collected. Investigators from institutions or trials who were known to have assessed and reported RCB in a pre-defined cohort were invited to participate between October, 2018, and April, 2019 (and all accepted); pooled data was finalised in November, 2019. Participating investigators representing 12 groups (four trials and eight clinical cohorts; appendix pp 2–3) from Europe and the USA provided individual patient data. We provide references or registration numbers for trials and cohorts when available. The following trials were included: the I-SPY 1 trial,17 the I-SPY 2 trial,18,20 the ARTemis trial,16 and a trial led by the Instituto de Investigación Sanitaria Gregorio Marañón (IISGM; Madrid, Spain).19 Two of the trials included investigational therapies: the ARTemis study, in which bevacizumab was the investigational drug; and I-SPY 2, in which nine investigational drugs were adaptively randomised (4:1) against a concurrent control.18,20 I-SPY 1